1. printed by
www.postersession.com
DATAAND RESULTS
Innovotech MBEC High Throughput-Assay3
Spectrophotometry and Optical Density
Ciprofloxacin Hydrochloride
1. American Lung Association, 2010.
2. Cystic Fibrosis Foundation, 2014.
3. MBEC Assay Procedural Manual for High-Throughput Antimicrobial
Susceptibility Testing of Biofilms, Version 1. Innovotech, Inc. 2012.
• Maintaining bacterial sterility is extremely difficult.
• Using a drug concentration that is known to be effective over a particular
time period, a minimum eradication concentrations can be determined
through the use of serial dilutions and statistical analysis.
• To qualify for minimum eradication, the bacterial density to which the drug
is applied must be significantly similar to the density of the sterility control
and significantly different from the density of the growth control.
• Over a 24 hour challenge period, the Ciprofloxacin-HCl concentration of
0.488 ug/mL effectively performs as a minimum eradication concentration
against planktonic P. Aeruginosa dispersed from a biofilm.
• Over a 24 hour challenge period, the Ciprofloxacin-HCl concentration of
0.977 ug/mL effectively performs as a minimum eradication concentration
against recently formed P. Aeruginosa biofilms.
• Over a 24 hour challenge period, none of the applied concentrations
effectively performed as minimum eradication concentrations against a 24
hour inoculation consisting of both planktonic and biofilm P. Aeruginosa.
Future Work
• Additional tests should be performed not only to confirm these results, but
also to determine a minimum bacterial eradication concentration of drug
against previously-inoculated, high-density bacteria.
• Once a minimum dosage has been determined, the drug should be
encapsulated into polymeric nanospheres as a delivery method.
• Eventually, the bacteria should be seeded onto mucus-producing human
cells, and the polymeric nanospheres should be tested for their ability to
effectively deliver the drug and eradicate the bacteria with minimal harm to
the human cells.
• Cystic Fibrosis is a life-threatening, genetic disorder causing lungs and
airways to accumulate mucus, providing ideal conditions for bacteria.1
• Of the 70,000 people affected worldwide, as many as 85% of Cystic Fibrosis
patients are chronically affected by Pseudomonas Aeruginosa infections.2
• The goal of this experiment is to develop a method for determining the
susceptibility of Pseudomonas Aeruginosa bacteria in planktonic and biofilm
states to the application of varying concentrations of a known bactericide.
MATERIALS AND METHODS
PURPOSE CONCLUSION
ACKNOWLEDGEMENTS
C
EF
EF
EF
EF
A
REFERENCES
Special thanks to Dr. Hugh Smyth for providing me with the opportunity and
equipment to conduct research as a member of his lab and stimulating my
passion for science.
Additional thanks to Tania Bahamondez-Cañas, Dr. Kristin Fathe, and
Dr. Nihal Bandara for encouraging consultations and experimental assistance.
Antimicrobial Susceptibility of Pseudomonas Aeruginosa
Kevin Gandingco, Jessica Musler, Hugh Smyth, PhD
Department of Biomedical Engineering & College of Pharmacy, The University of Texas at Austin
Smyth Lab
Drug Delivery & Pharmaceutics
MonochromatorLight Source Sample Detector
β αββ β α α α
ε
ββββ
ε
ε